FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
FDA has accepted a biologics license application (BLA) from Eli Lilly and Company to review galcanezumab, a monoclonal antibody (mAb) being developed to prevent migraine in adults, Lilly announced on Dec. 11, 2017. The biologic has been submitted for use as a once-monthly, self-administered injection in an auto-injector pen or prefilled syringe. Lilly announced the submission of the BLA in its third-quarter earnings call in October 2017.
Galcanezumab is specifically designed to bind to and inhibit the activity of calcitonin gene-related peptide (CGRP), which is believed to play a role in migraine and cluster headache. It is a part of Lilly’s pain portfolio and represents the first of three investigational, non-opioid treatments in development by the company. The portfolio also includes lasmiditan, for the acute treatment of migraine, and tanezumab, developed in partnership with Pfizer, for treating osteoarthritis, chronic low back pain, and cancer pain.
Source: Eli Lilly and Company
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.